Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks

ISSN： 1172-7047

Source： CNS Drugs, Vol.25, Iss.5, 2011-05, pp. : 383-399

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefits and Risks of Antipsychotic Polypharmacy: An Evidence-Based Review of the Literature

By Tranulis Constantin

Drug Safety, Vol. 31, Iss. 1, 2008-01 ,pp. : 7-20

Adis International

Access to resources Recommend Favorite

Antipsychotic polypharmacy in schizophrenia in Canada

Inpharma, Vol. 1, Iss. 1296, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Antipsychotic Polypharmacy

Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. : 2231-2238

Bentham Science Publishers

Access to resources Recommend Favorite

Increase in Antipsychotic Polypharmacy Treatment in Patients with Schizophrenia Between 1994-2000 and 2010

By Ceylan Deniz Aktener Ahmet B. Akdede Berna Alptekin Koksal

Current Psychopharmacology, Vol. 3, Iss. 2, 2014-08 ,pp. : 108-112

Bentham Science Publishers

Access to resources Recommend Favorite

Increase in Antipsychotic Polypharmacy Treatment in Patients with Schizophrenia Between 1994-2000 and 2010

Current Psychopharmacology, Vol. 3, Iss. 2, 2014-08 ,pp. : 108-112

Bentham Science Publishers

Access to resources Recommend Favorite